北京若生智能科技有限公司
Drug Database
PR

pregabalin (pregabalin, YuHan / YHD 1119 / YHD1119)

✓ Approved

YuHan · CACNA2D1 · 小分子

什么是 pregabalin？

pregabalin 是一种小分子，由YuHan研发。该药已获批，用于治疗相关适应症，给药途径：Oral (PO)。

药物档案

商品名pregabalin, YuHan, YHD 1119, YHD1119
公司YuHan
药物类别小分子
分子靶点CACNA2D1
给药途径Oral (PO)
状态Approved
来源： ClinicalTrials.gov, YuHan

作用机制

分子靶点

pregabalin 作用于 1 个分子靶点：

CACNA2D1calcium voltage-gated channel auxiliary subunit alpha2delta 1 (LINC01112, CACNA2)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

pregabalin 针对 2 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Nervous system disordersDiabetic neuropathy✓ Approved
Nervous system disordersPost herpetic neuralgia✓ Approved

相关研究文献

PubMedDiabetes therapy : research, treatment and education of diabetes and related disorders2026-10-26

A Malaysian Expert Consensus on The Identification, Evaluation, and Pharmacological Management of Diabetic Sensorimotor Polyneuropathy.

Lim Lee-Ling LL, Foo Siew-Hui SH, Abdul Ghani Rohana R, Ibrahim Luqman L et al.

Diabetic sensorimotor polyneuropathy (DSPN), the most common form of diabetic peripheral neuropathy (DPN), is a chronic complication of diabetes associated with sensory loss, foot ulceration, lower-limb amputation, reduced quality of life, and increased mortality. Despite its substantial clinical burden, DSPN remains underdiagnosed and undertreated in Malaysia. This consensus aimed to develop practical, evidence-informed recommendations for screening, diagnosis, and management of painful and non-painful presentations of DSPN tailored to the Malaysian healthcare setting. An expert panel comprising 11 endocrinologists from public and private healthcare institutions in Malaysia was convened. Draft recommendations were adapted from international and local guidelines for Malaysian clinical practice. Consensus development involved pre-meeting review and anonymous voting, followed by structured face-to-face discussion. Consensus was defined as ≥80% agreement. The panel finalized 61 consensus statements covering screening, diagnosis, sensory examination, and treatment. Recommendations emphasize annual screening for all individuals with diabetes and clinical examination to detect sensory deficits, including in individuals without painful symptoms. Assessment should include multiple bedside tests to evaluate small- and large-fiber function and loss of protective sensation. Recommended tests include the 10-g monofilament, vibration and pin-prick testing, and the Ipswich Touch Test, particularly in resource-limited settings. Assessment of painful and non-painful symptoms should complement rather than replace objective examination. Validated screening questionnaires, including the Malay-language PainDETECT may support assessment. Management includes optimization of glycemic control, lifestyle interventions, adjunctive pathogenetically oriented therapies such as alpha-lipoic acid, and evidence-based pharmacological treatments including pregabalin, gabapentin, duloxetine, and tricyclic antidepressants. Routine opioid use is discouraged. This Malaysian expert consensus provides practical, context-specific recommendations for early detection, diagnosis, and management of DSPN. By adapting international guidance to local healthcare realities, these recommendations aim to improve care consistency, reduce DSPN-related complications, and enhance patient outcomes in Malaysia.

PMID 42928304
阅读全文 →
PubMedTalanta2026-10-25

Effervescent-tablet-integrated derivatization and salting-out extraction for LC-FLD determination of neuropathic pain drugs in human plasma.

Gao Yaping Y, Zhang Xiaofei X, Wang Lanjie L, Ma Yixin Y et al.

Reliable measurement of neuropathic pain medications in plasma is required for pharmacokinetic evaluation and therapeutic monitoring; however, their high polarity and weak intrinsic UV/fluorescence signals complicate chromatographic detection. We therefore established a one-pot procedure in which a multifunctional effervescent tablet enables effervescence-assisted derivatization and salting-out liquid-liquid extraction (EAD-SALLE) for pregabalin, gabapentin, and mirogabalin. Each preprepared tablet (8 mm in diameter and 2 mm thick) contained 2.3 mg of 6-aminoquinolyl-N-hydroxysuccinimidyl carbamate (AQC), together with 108.7 mg of Na2CO3 and 47.3 mg of NaH2PO4 (molar ratio, 2.6:1). Introducing the tablet into the aqueous sample-acetonitrile system triggered CO2-mediated mixing, established the required pH, promoted AQC labeling, and induced phase separation; the combined pretreatment was completed in a single tube within approximately 3.5 min. Analyte peak areas obtained using tablets stored dry for 3 months were similar to those obtained using fresh tablets. The assay afforded coefficients of determination above 0.999, limits of detection of 0.011-0.023 μg/mL, relative standard deviations not exceeding 10.71%, and relative recoveries of 96.13-108.42%. Analysis of the tested plasma samples indicated that the platform provides a rapid, practical, and economical route to LC-FLD analysis of these drugs.

PMID 42925680
阅读全文 →
PubMedFrontiers in immunology2026-10-24

Facial pruritus and stiffness as the initial manifestations of glycine receptor antibody-positive progressive encephalomyelitis with rigidity and myoclonus: a case report and literature review.

Zhang Qiang Q, Li Jie J, Tang Jianguang J, Fang Jia J

Progressive encephalomyelitis with rigidity and myoclonus (PERM) is a rare and severe phenotype within stiff-person spectrum disorders (SPSD), frequently associated with glycine receptor antibodies (GlyR-Ab). Because typical rigidity and stimulus-sensitive spasms may be absent at disease onset, early diagnosis can be challenging. We report a 52-year-old man who presented with facial pruritus, facial stiffness, limited tongue protrusion, dysphagia, and left lower-limb pain. Early manifestations included diplopia, restricted extraocular movements, dysarthria, restricted mouth opening, involuntary jaw closure resembling trismus, and involuntary tongue biting. Nonspecific oropharyngeal and maxillofacial abnormalities on imaging initially raised concern for infectious multiple cranial neuropathy, tetanus, or orofacial infection; however, antimicrobial therapy and symptomatic treatment with diazepam and pregabalin produced no sustained improvement. The subsequent emergence of neck, truncal, and lower-limb stiffness, gait impairment, perioral hypersensitivity, and stimulus-induced facial muscle contractions prompted reconsideration of SPSD. Needle electromyography (EMG) demonstrated continuous synchronous motor unit activity in agonist and antagonist muscles at rest. Serum antibody testing was positive for glycine receptor 1 immunoglobulin G (GlyR1-IgG), with a reported semiquantitative value of 1:100, whereas serum glutamic acid decarboxylase 65 (GAD65) antibody was negative, supporting the diagnosis of GlyR-Ab-positive PERM. The patient showed marked initial improvement following combined immunotherapy and symptomatic treatment. During regular follow-up, the patient's symptoms progressively improved. At the latest follow-up, diplopia, facial sensory abnormalities, restricted mouth opening, and limb rigidity had resolved. Repeat serum testing at a different laboratory showed persistent GlyR1-IgG positivity, with a reported endpoint titer of 1:100; the two numerical results were not directly comparable because different titration protocols were used. The patient was advised to continue oral mycophenolate mofetil 500 mg twice daily as maintenance therapy. This case illustrates the diagnostic challenges of GlyR-Ab-positive PERM when facial pruritus and cranial-bulbar symptoms precede generalized stiffness. Recognition of evolving stimulus-induced muscle contractions, together with characteristic EMG findings and antibody testing, can help distinguish this presentation from infectious cranial neuropathy, tetanus, and local orofacial disease.

PMID 42920638
阅读全文 →
PubMedJACC. Case reports2026-10-23

Systemic Amyloidosis After Liver Transplantation From a Donor With Hereditary Transthyretin Amyloidosis.

Machado Moises Abtibol MA, Monteiro Matheus Martins MM, Corrêa de Miranda Denison Clark DC, Oliveira de Azevedo Marcela M et al.

Acquired transthyretin (TTR) amyloidosis after domino liver transplantation is rare and may manifest years after the procedure, with neurologic involvement. A 75-year-old man received a liver from a donor with TTR amyloid polyneuropathy. Twelve years later, he developed paresthesias, diarrhea, and blood pressure lability. Electroneuromyography showed a length-dependent, predominantly axonal sensorimotor polyneuropathy, with absent sympathetic skin responses, indicating autonomic involvement. Abdominal fat pad biopsy was Congo red positive, and TTR genetic testing was negative. Cardiac involvement was absent. He was treated with pregabalin and fludrocortisone, and patisiran was indicated as disease-modifying therapy. The association of progressive neuropathy, dysautonomia, gastrointestinal manifestations, and domino transplantation favored acquired TTR amyloidosis over diabetic neuropathy. Reported cases show onset after 5-10 years, with neuropathy preceding cardiac disease. Domino transplant recipients require long-term follow-up, even with negative genetic testing and no initial cardiomyopathy, to enable early diagnosis and monitoring of systemic progression.

PMID 42910790
阅读全文 →
PubMedDermatitis : contact, atopic, occupational, drug2026-10-21

Letter: Refractory Aquagenic Pruritus Controlled with Pregabalin.

Khalil Nicole N, Coscarella Giulia G, Almeida Alana A, Chang Christopher C et al.

PMID 42902483
阅读全文 →
PubMedPain research & management2026-10-20

Towards Restoring Dopaminergic Balance in Fibromyalgia: The Untapped Potential of Nonpharmacological Interventions.

Spinetti Davide D, Sarlo Michela M, Sfriso Paolo P, Ramonda Roberta R et al.

Fibromyalgia (FM) is a chronic syndrome characterized by widespread pain, cognitive dysfunction, and mood disturbances. Growing evidence suggests that dopaminergic dysregulation may play a role in the pathophysiology of FM, linking reduced dopamine function to altered pain perception, anhedonia, fatigue, and impaired cognition. While pharmacological treatments-such as duloxetine, milnacipran, and pregabalin-may influence dopamine only indirectly, dopaminergic agonists like pramipexole have shown partial efficacy. Nonpharmacological interventions, including exercise, mindfulness, cognitive behavioral therapy (CBT), and noninvasive brain stimulation (NIBS), consistently improve symptoms, but their potential impact on dopamine pathways remains largely unexplored. This narrative-short review highlights a critical knowledge gap regarding dopaminergic modulation by nonpharmacological strategies and proposes a paradigm shift to be tested in future FM research. Future longitudinal, multimodal studies integrating neuroimaging, dopaminergic biomarkers, and clinical outcomes are required to test whether combined interventions exert synergistic effects on dopamine circuits. The validation of dopaminergic biomarkers to stratify patients according to their individual neurobiological profiles represents a critical step toward transitioning from a 'one-size-fits-all' approach to a precision medicine paradigm, enabling the development of tailored interventions aimed at restoring dopaminergic balance and, ultimately, improving pain, mood, cognition, and quality of life in FM patients.

PMID 42899600
阅读全文 →

注册免费账户还可查看另外 5388 篇文献

免费注册查看全部文献 →

了解更多pregabalin